Practical management of opioid rotation and equianalgesia

被引:75
作者
Treillet, Erwan [1 ]
Laurent, Sophie [2 ]
Hadjiat, Yacine [3 ]
机构
[1] Hop Lariboisiere, AP HP, Med Douleur & Med Palliat, 2 Rue Ambroise Pare, F-75010 Paris, France
[2] Inst Gustave Roussy, Inst Cancerol, Villejuif, France
[3] Mundipharma France, Paris, France
来源
JOURNAL OF PAIN RESEARCH | 2018年 / 11卷
关键词
opioid rotation; opioid switching; equianalgesic dose; morphine; hydromorphone; oxycodone; fentanyl; CONTROLLED-RELEASE OXYCODONE; CANCER PAIN; TRANSDERMAL FENTANYL; PALLIATIVE CARE; ORAL OXYCODONE; ANALGESIC EQUIVALENCE; SUBCUTANEOUS MORPHINE; CLINICAL-EFFICACY; CONVERSION RATIO; DOSE RATIOS;
D O I
10.2147/JPR.S170269
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: To review the recent literature on opioid rotation (ie, switching from one opioid drug to another or changing an opioid's administration route) in cancer patients experiencing severe pain and to develop a novel equianalgesia table for use in routine clinical practice. Methods: The MEDLINE database was searched with terms "cancer pain," "opioid rotation," "opioid switching," "opioid ratio," "opioid conversion ratio," and "opioid equianalgesia" for the major opioids (morphine, oxycodone, fentanyl, and hydromorphone) and the intravenous, subcutaneous, oral, and transdermal administration routes. Selected articles were assessed for the calculated or cited opioid dose ratio, bidirectionality, and use of the oral morphine equivalent daily dose or a direct drug-to-drug ratio. Results: Twenty publications met our selection criteria and were analyzed in detail. We did not find any large-scale, prospective, double-blind randomized controlled trial with robust design, and most of the studies assessed relatively small numbers of patients. Bidirectionality was investigated in seven studies only. Conclusion: The updated equianalgesic table presented here incorporates the latest data and provides information on bidirectionality. Despite the daily use of equianalgesic tables, they are not based on high-level scientific evidence. More clinical research is needed on this topic.
引用
收藏
页码:2587 / 2601
页数:15
相关论文
共 85 条
  • [1] Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life
    Ahmedzai, S
    Brooks, D
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 13 (05) : 254 - 261
  • [2] Accuracy in equianalgesic dosing: Conversion dilemmas
    Anderson, R
    Saiers, JH
    Abram, S
    Schlicht, C
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2001, 21 (05) : 397 - 406
  • [3] Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain
    Babul, N
    Provencher, L
    Laberge, F
    Harsanyi, Z
    Moulin, D
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (01) : 74 - 81
  • [4] BEAVER WT, 1978, J PHARMACOL EXP THER, V207, P92
  • [5] Berdine Hildegarde J, 2006, J Pain Palliat Care Pharmacother, V20, P79, DOI 10.1300/J354v20n04_16
  • [6] Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain
    Bruera, E
    Belzile, M
    Pituskin, E
    Fainsinger, R
    Darke, A
    Harsanyi, Z
    Babul, N
    Ford, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) : 3222 - 3229
  • [7] Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO
  • [8] 2-T
  • [9] CLINICAL EFFICACY AND SAFETY OF A NOVEL CONTROLLED-RELEASE MORPHINE SUPPOSITORY AND SUBCUTANEOUS MORPHINE IN CANCER PAIN - A RANDOMIZED EVALUATION
    BRUERA, E
    FAINSINGER, R
    SPACHYNSKI, K
    BABUL, N
    HARSANYI, Z
    DARKE, AC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) : 1520 - 1527
  • [10] Chronic Opioid Therapy and Preventive Services in Rural Primary Care: An Oregon Rural Practice-based Research Network Study
    Buckley, David I.
    Calvert, James F.
    Lapidus, Jodi A.
    Morris, Cynthia D.
    [J]. ANNALS OF FAMILY MEDICINE, 2010, 8 (03) : 237 - 244